Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510582 | 0.95 | P2RX7 (0.56) | P2RX7EPHX1LMNASMN1; SMN2GAA | |
| SCHEMBL4518526 | 0.94 | P2RX7 (0.49) | P2RX7MCHR1EPHX1LMNASMN1; SMN2 | |
| SCHEMBL13958661 | 0.93 | P2RX7 (0.54) | P2RX7EPHX1LMNASMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL4508098 | 0.92 | P2RX7 (0.53) | P2RX7LMNASMN1; SMN2GAACYP2C19 | |
| SCHEMBL13958662 | 0.92 | P2RX7 (0.53) | P2RX7EPHX1LMNASMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL4506962 | 0.91 | P2RX7 (0.52) | P2RX7EPHX1LMNASMN1; SMN2GAA | |
| SCHEMBL13958663 | 0.90 | P2RX7 (0.57) | P2RX7LMNASMN1; SMN2GAACYP2C19 | |
| SCHEMBL4507891 | 0.90 | P2RX7 (0.56) | P2RX7LMNASMN1; SMN2GAACYP2C19 | |
| SCHEMBL6529019 | 0.90 | P2RX7 (0.56) | P2RX7LMNASMN1; SMN2GAACYP2C19 | |
| Hydrochloric Acid SCHEMBL4510959 | 0.89 | P2RX7 (0.57) | P2RX7LMNASMN1; SMN2GAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182874-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | claimed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20080182874-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182874-A1 | Novel Compounds | REN, F12, GPR119 | P2RX7 1672/4885MCHR1 1504/4885EPHX1 458/4885 |
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 554/4885MCHR1 156/4885EPHX1 598/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885MCHR1 198/4885EPHX1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.